New study brings personalized immunotherapy prescriptions a step closer UniOfBath
, making themselves invisible to the natural anti-tumor response and actively blocking it. One type of immunotherapy, called immune checkpoint inhibitors, involves antibodies that remove the brakes that the tumor has applied to the immune system. This re-activates the patients' natural anti-cancer response, which then destroys the tumor.
To investigate the role of these types of the immune checkpoint regulators in cancer patients, the research team from the Bergonie Cancer Institute and University of Bath professors Banafshe Larijani and Stephen Ward recruited patients with metastatic lung tumors who were undergoing a treatment calledIn some cases, treating tumors in one lung using RFA can cause tumors in the other lung to also reduce in size.
This is the first time these interactions have been quantified within RFA patients, and they show that engagement did not correlate with the quantity of protein present—meaning that the prescribing based on the levels of proteins present is unlikely to be suitable. "Moreover, we're delighted that the study shows iFRET provides a method for advanced quantitative immune surveyance—as opposed to qualitative immune surveyance—of patients, which will greatly increase patient access to precision medicine."
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Sandra Nunnerley launches sculptural Corian tables that nod to the starsMade exclusively for New York’s Maison Gerard, Sandra Nunnerley’s sleek new Corian tables feature bronze inlay
Læs mere »
Shropshire's new fire chief to take over in the new yearA new fire chief is set to take over the reigns in Shropshire in the new year.
Læs mere »
The Walking Dead's Maggie and Negan return in first teaser for Dead City spinoffThe pair are facing new threats in New York.
Læs mere »
Target product profiles for novel medicines to prevent and treat preeclampsia: An expert consensusBackground Preeclampsia and eclampsia are a leading cause of global maternal and newborn mortality. Currently, there are few effective medicines that can prevent or treat preeclampsia. Target Product Profiles (TPPs) are important tools for driving new product development by specifying upfront the characteristics that new products should take. Considering the lack of investment and innovation around new medicines for obstetric conditions, we aimed to develop two new TPPs for medicines to prevent and treat preeclampsia. Methods and findings We used a multi-methods approach comprised of a literature review, stakeholder interviews, online survey, and public consultation. Following an initial literature review, diverse stakeholders (clinical practice, research, academia, international organizations, funders, consumer representatives) were invited for in-depth interviews and an online international survey, as well as public consultation on draft TPPs. The level of stakeholder agreement with TPPs was assessed, and findings from interviews were synthesised to inform the final TPPs. We performed 23 stakeholder interviews and received 46 survey responses. A high level of agreement was observed in survey results, with 89% of TPP variables reaching consensus (75% agree or strongly agree). Points of discussion were raised around the target population for preeclampsia prevention and treatment, as well as the acceptability of cold-chain storage and routes of administration. Conclusion There is consensus within the maternal health research community on the parameters that new medicines for preeclampsia prevention and treatment must achieve to meet real-world health needs. These TPPs provide necessary guidance to spur interest, innovation and investment in the development of new medicines to prevent and treat preeclampsia.
Læs mere »